Bio & health

Machine-learning prediction and monitoring studies clustered around acute and critical care.

Cancer news spanned an FDA advisory vote, a new approval and registered combination trials.

AI-assisted modelling and triage tools met a resurgent filovirus and a deep-time lesson on plague.

A preprint used genomic language modelling to design biosynthetic pathways while clinical work pushed new biomarkers.

Brain science ranged from a two-organ hypothesis to implants, long-COVID imaging and dementia prediction.

A capital-markets-day reset for Novo landed alongside a meta-regression on GLP-1 stroke and cognitive outcomes.

A Galleri advisory-committee vote, a Lilly approval and a radiopharma merger set the day's regulatory tone.

Clinical AI moved from benchmarks toward deployment — and one paper flagged a gap between algorithmic scores and decisions.

Resilience, not only pathology, is emerging as the predictive variable in dementia research.

Editing and RNA therapies advanced, and researchers solved a 50-year mystery by finding a new human blood group.

An effectiveness study and a trust-and-information story show the two halves of the vaccination problem.

Flu antigenic drift, repeated SARS-CoV-2 introductions and a surging Ebola relative point to the value of early warning.

New disease models, an Amish cohort study and an analysis of repurposing candidates all point at the same target from different directions.

Papers on AI in trials, patient-facing generative AI and a geriatrician's commentary converge on evaluation as the binding constraint.

An approval for an ultra-rare disease arrived alongside preclinical gene-therapy work and a review of CRISPR-based biosensors.

A first-in-human neuromodulation trial overlaps with basic work on how amygdala neurons join valence-related ensembles and with a developmental study of anxiety.

Observational diet research and two cardiovascular studies on gut microbiota and on religiosity add to the evidence base without settling causation.

New and updated registry entries spanned AI cardiac imaging, a supplement trial, metabolic and oncology studies, and an AI review of diabetes self-management.